Nebkliq (Amlodipine Besilate, Nebivolol Hydrochloride)

• Nebkliq combines a calcium‑channel blocker and a beta‑blocker to manage elevated blood pressure.
• Hypertension: provides sustained reduction of systolic and diastolic pressure in adults.
• Essential hypertension: improves long‑term blood pressure control and reduces cardiovascular risk.
• Isolated systolic hypertension: lowers high systolic values while maintaining diastolic stability.

• Amlodipine besilate inhibits L‑type calcium channels in vascular smooth muscle, causing vasodilation and reduced peripheral resistance. Nebivolol hydrochloride selectively blocks β1‑adrenergic receptors, decreasing heart rate and cardiac output, and also stimulates endothelial nitric‑oxide release, further promoting vasodilation. The combined actions result in lowered arterial pressure.

Nebkliq may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness, especially on standing.
• Flushing: transient warmth and redness.
• Fatigue or tiredness.
• Nausea or abdominal discomfort.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure.
• Bradycardia: unusually slow heart rate.
• Heart block or atrioventricular conduction disturbances.
• Angioedema: swelling of face, lips, or throat.
• Hepatic dysfunction: abnormal liver enzymes.
• Allergic reactions: rash, itching, or anaphylaxis.

Before initiating Nebkliq, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Cardiac assessment: review heart rate and conduction status.
• Hepatic impairment: adjust use in patients with liver disease.
• Concomitant antihypertensives: avoid additive effects that may cause severe hypotension.
• Abrupt discontinuation: taper gradually to prevent rebound hypertension.
• Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Nebkliq can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels.
• Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): risk of excessive bradycardia.
• Other antihypertensives (e.g., ACE inhibitors, ARBs) at high doses: may cause profound hypotension.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• NSAIDs or COX‑2 inhibitors: can blunt antihypertensive effect.
• Diuretics: may enhance electrolyte disturbances.
• Antidiabetic agents: monitor glucose as blood pressure changes can affect glycemic control.